Navigation Links
Questcor to Commence Phase 2 Study of Acthar for ALS
Date:7/24/2013

l need such as ALS. Questcor also has agreed to acquire certain international rights for Synacthen® (tetracosactide) and Synacthen Depot®, and has licensed the right to develop and seek FDA approval for these products in the United States.  For more information about Questcor, please visit www.questcor.com.  For more information about Acthar, including important safety information, please visit www.acthar.com.

Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "believes," "continue," "could," "estimates," "expects," "growth," "intent," "may," "plans," "potential," "should," "substantial," "will," or "would" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:

  • Research and development risks, including risks associated with Questcor's work in the area of ALS;
  • Our reliance on Acthar for substantially all of our net sales and profits;
  • The lack of patent protection for Acthar; and the possible FDA approval and market introduction of competitive products;
  • The results of any pending or future litigation, investigations or claims, including with respect to the investigation by the United States Attorney's Office for the Eastern District of Pennsylvania regarding the Company's promotional practices and litigation brought by certain
    '/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Questcor to Report Second Quarter Financial Results on July 30, 2013
2. Questcor to Initiate Pilot Commercialization Effort In Pulmonology for Symptomatic Sarcoidosis
3. Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx, Questcor, and ImmunoGen
4. Questcor Adds Angus C. Russell to Board of Directors
5. Questcor Reports First Quarter Financial Results
6. Questcor to Report First Quarter Results on April 30, 2013
7. Questcor Reports Fourth Quarter and Full Year 2012 Results
8. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
9. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
10. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
11. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014  XBiotech announced today interim results ... in the US for its anti-cancer agent Xilonix™. ... therapy, is being evaluated in advanced colorectal cancer ... The primary endpoint of the study is overall ... a control population provided only palliative therapy for ...
(Date:9/2/2014)... CALGARY, Alberta , September 2, 2014 ... of the Art and Featured Research Session" beim Kongress ... (TSX: RVX) gab heute bekannt, dass Dr. Jan Johansson, Senior ... des europäischen Kardiologenverbandes (ESC) 2014 in Barcelona ... Vortrag mit dem Titel " Effects of RVX-208 on ...
(Date:9/2/2014)... Reportlinker.com announces that a new market ... Acute Heart Failure Global Clinical Trials Review, ... Acute Heart Failure Global Clinical Trials ... clinical trial report, "Acute Heart Failure Global Clinical ... Acute Heart Failure clinical trial scenario. This report ...
Breaking Medicine Technology:XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 2RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 3RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 4RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 5RVX-208 führt bei Patienten mit Diabetes mellitus zu einer Verringerung des relativen Risikos von gravierenden unerwünschten Herzkreislaufereignissen um 77 % 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8
(Date:9/2/2014)... (PRWEB) September 02, 2014 - Molecular ... as a class of diagnostic test that analyzes proteins ... nucleic acids and proteins that belong to individual patients ... health condition, or risk of developing a specific disease. ... known as (MDx) evaluating the new class of diagnostic ...
(Date:9/2/2014)... A New York City based company ... simple, yet revolutionary, product that will have ... health care costs for Americans. , REMIND-A-CAP™ ... puts control in the user's hands. It's a simple ... next date of intake by simply turning a knob. ...
(Date:9/2/2014)... A little white pill may help scientists learn why ... their peers, even if their lungs are relatively healthy. ... marketed as Revatio to treat pulmonary hypertension and Viagra ... of over-the-counter antioxidants will help them identify the root ... for these patients. , "We want to understand ...
(Date:9/2/2014)... over antibiotic ointment, there might be a new salve to ... an unlikely placethe lowly salamander. Salamanders may not be the ... achieve amazing recovery of seriously damaged body parts. Now, a ... The FASEB Journal , identifies a small protein ... be the key to unlocking the secret of this amazing ...
(Date:9/2/2014)... Society of Nuclear Medicine and Molecular Imaging (SNMMI) is ... Wagner-Torizuka Fellowship. This two-year fellowship, founded in 2008 by ... late Kanji Torizuka, MD, PhD, is designed to provide ... medicine and molecular imaging for Japanese physicians in the ... is proud to sponsor the Wagner-Torizuka Fellowship. This program ...
Breaking Medicine News(10 mins):Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 2Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 3Health News:Molecular Diagnostic Market: Global Factors and Perspectives by Transparency Market Research 4Health News:REMIND-A-CAP™ , A New York City Based Company Invents Groundbreaking Prescription Cap to Curb Non-Adherence 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 2Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 3Health News:Drug that improves blood flow may help find cause of exercise intolerance in cystic fibrosis 4Health News:Salamander skin peptide promotes quick and effective wound healing in mice 2Health News:SNMMI 2014-2016 Wagner-Torizuka Fellowship recipients announced 2
... March is National Brain Injury Awareness MonthWHEATON, Ill., March 18 ... to 3.8 million individuals in the U.S. each year according ... is a type of traumatic brain injury (TBI) caused by ... from mild to severe. It is important to note that ...
... "The White House made the correct decision ... Veterans Affairs to have military veterans, personal insurance ... said VAdm. Norb Ryan, Jr., USN-Ret., president of ... said he advised President Obama that "pursuing this ...
... passage of life-saving legislationNEW YORK, March 18 The ... to finding a cure for life-threatening food allergies, will ... and Mental Hygiene (DOHMH) to create an educational poster ... In addition to working with DOHMH to develop ...
... Pelosi announced this afternoon that the Obama Administration would not ... use their private insurance to pay for the treatment of ... meeting she and House Democrats hosted this afternoon in the ... news with a standing ovation. Below are the Speaker,s remarks. ...
... taking statins, drugs typically used to prevent heart attacks ... doctors report in a new study. , Doctors have ... attacks and strokes in patients who have already had ... been shown to have a protective effect for patients ...
... Development Group, Inc., a leader in software solutions ... services markets, is pleased to introduce PsychConsult Provider(R) ... focused on creating a completely paperless environment with ... record (EMR), and streamlined revenue cycle management.Highlights of ...
Cached Medicine News:Health News:Sports Concussions: Common and Preventable 2Health News:White House Makes Correct Decision On Veterans Insurance Proposal 2Health News:Food Allergy Initiative to Partner With NYC Department of Health on Educational Poster for Restaurants Citywide 2Health News:Food Allergy Initiative to Partner With NYC Department of Health on Educational Poster for Restaurants Citywide 3Health News:Pelosi: Administration Will Not Force Veterans to Use Private Insurance to Pay for Treatment of Combat-Related Injuries 2Health News:6.5 million more patients might benefit from statins to prevent heart attacks, strokes 2Health News:Askesis Development Group, Inc. Launches New Behavioral Health Software for Electronic Medical Records (EMR) and Practice Management 2
Rapid reagent impregnated disk test for presumptive identification of Candida albicans....
... Electronic Medical Records for small and large ... from check-in to check-out. Review the complete ... medications, to allergies, labs and charts all ... your patient records immediately. Communicate electronically with ...
... Written specifically for urologists by ... utilizes touch screen technology to ... eliminate the use of a ... makes using an EMR faster ...
... a new generation of advanced Electronic Medical ... the largest, numerically codified medical vocabularies in ... data elements embedded in MedcomSoft Record, healthcare ... an easy and intuitive point and click ...
Medicine Products: